MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2

Wang,Siliang; Chen,Xiaodong; Tang,Meiyue

doi:10.3892/or.2014.3478

MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2

Authors:
- Siliang Wang
- Xiaodong Chen
- Meiyue Tang
View Affiliations

Affiliations: Department of Medical Oncology, Shengjing Hospital of China Medical University, Heping, Shenyang, Liaoning 110022, P.R. China
Published online on: September 15, 2014 https://doi.org/10.3892/or.2014.3478
Pages: 2824-2830

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)-216a expression is significantly downregulated in human pancreatic cancer, however, the underlying mechanism remains unknown. In the present study, we aimed to identify and characterize the direct target gene and potential function of miR-216a in pancreatic cancer cells. Bioinformatics analysis and dual-luciferase reporter gene assay showed that Janus kinase 2 (JAK2) was a direct target gene of miR-216a. Quantitative polymerase chain reaction and western blot analysis demonstrated that miR-216a decreased the mRNA and protein levels of JAK2 in pancreatic cancer cells. Phosphorylation of the signal transducer and activator of transcription 3 (STAT3) was also downregulated by miR-216a, whereas the anti-miR-216a treatment had an opposite effect. Treatment of pancreatic cancer cells with miR-216a significantly inhibited cell growth and promoted cell apoptosis. In addition, the downstream genes of JAK2/STAT3, survivin and X-linked inhibitor of apoptosis protein, which are anti‑apoptotic genes, were also decreased by miR-216a. Moreover, miR-216a overexpression markedly inhibited the JAK2/STAT3 signaling pathway and xenograft tumor growth in vivo. Compared with miR-216a treatment, anti-miR-216a treatment exhibited opposite effects throughout the entire experiment, confirming the inhibitory effect of miR-216a on pancreatic cancer by regulating the JAK2/STAT3 signaling pathway. The results provided evidence that miR-216a targeting JAK2 negatively regulated the development of pancreatic cancer cells and may be used to develop a miRNA-based therapeutic strategy against pancreatic cancer.

View Figures

View References

1	Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar
2	Kleeff J, Michalski CW, Friess H and Büchler MW: Surgical treatment of pancreatic cancer: the role of adjuvant and multimodal therapies. Eur J Surg Oncol. 33:817–823. 2007. View Article : Google Scholar : PubMed/NCBI
3	Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
4	Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 27:3778–3785. 2009. View Article : Google Scholar
5	Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 24:3946–3952. 2006. View Article : Google Scholar : PubMed/NCBI
6	Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
7	Schneider G and Schmid RM: Genetic alterations in pancreatic carcinoma. Mol Cancer. 2:152003. View Article : Google Scholar
8	Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N and Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20:1218–1249. 2006. View Article : Google Scholar : PubMed/NCBI
9	Chiu J and Yau T: Metastatic pancreatic cancer: are we making progress in treatment? Gastroenterol Res Pract. 2012:8989312012. View Article : Google Scholar : PubMed/NCBI
10	Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. Cell. 148:1172–1187. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
12	Winter J, Jung S, Keller S, Gregory RI and Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
13	Lujambio A and Lowe SW: The microcosmos of cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
14	Drakaki A and Iliopoulos D: MicroRNA-gene signaling pathways in pancreatic cancer. Biomed J. 36:200–208. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hou B, Jian Z, Chen S, et al: Expression of miR-216a in pancreatic cancer and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao. 32:1628–1631. 2012.(In Chinese).
16	Link A, Becker V, Goel A, Wex T and Malfertheiner P: Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. PLoS One. 7:e429332012. View Article : Google Scholar : PubMed/NCBI
17	Yu J, Li A, Hong SM, Hruban RH and Goggins M: MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res. 18:981–992. 2012. View Article : Google Scholar : PubMed/NCBI
18	Scholz A, Heinze S, Detjen KM, et al: Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology. 125:891–905. 2003. View Article : Google Scholar : PubMed/NCBI
19	Zhong Z, Wen Z and Darnell JE Jr: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
20	Shuai K, Horvath CM, Huang LH, et al: Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell. 76:821–828. 1994. View Article : Google Scholar : PubMed/NCBI
21	Chan KS, Sano S, Kiguchi K, et al: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest. 114:720–728. 2004. View Article : Google Scholar : PubMed/NCBI
22	Wang T, Niu G, Kortylewski M, et al: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 10:48–54. 2004. View Article : Google Scholar : PubMed/NCBI
23	Frank DA: STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251:199–210. 2007. View Article : Google Scholar : PubMed/NCBI
24	Kumar C, Purandare AV, Lee FY and Lorenzi MV: Kinase drug discovery approaches in chronic myeloproliferative disorders. Oncogene. 28:2305–2313. 2009. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Ali S, Banerjee S, Logna F, et al: Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol. 227:3373–3380. 2012. View Article : Google Scholar : PubMed/NCBI
27	Jeyapalan Z, Deng Z, Shatseva T, et al: Expression of CD44 3′-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res. 39:3026–3041. 2011.
28	Kato M, Putta S, Wang M, et al: TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 11:881–889. 2009.
29	Kato M, Wang L, Putta S, et al: Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-β-induced collagen expression in kidney cells. J Biol Chem. 285:34004–34015. 2010.PubMed/NCBI
30	Chen PJ, Yeh SH, Liu WH, et al: Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology. 56:632–643. 2012. View Article : Google Scholar : PubMed/NCBI
31	Usborne AL, Smith AT, Engle SK, et al: Biomarkers of exocrine pancreatic injury in 2 rat acute pancreatitis models. Toxicol Pathol. 42:195–203. 2014. View Article : Google Scholar : PubMed/NCBI
32	Blenkiron C, Askelund KJ, Shanbhag ST, et al: MicroRNAs in mesenteric lymph and plasma during acute pancreatitis. Ann Surg. Feb 6–2014.(Epub ahead of print).
33	Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
34	Gabler K, Behrmann I and Haan C: JAK2 mutants (e.g, JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT. 2:e250252013.PubMed/NCBI
35	Miao L, Liu K, Xie M, Xing Y and Xi T: miR-375 inhibits Helicobacter pylori-induced gastric carcinogenesis by blocking JAK2-STAT3 signaling. Cancer Immunol Immunother. 63:699–711. 2014.
36	Corcoran RB, Contino G, Deshpande V, et al: STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 71:5020–5029. 2011. View Article : Google Scholar : PubMed/NCBI
37	Miyatsuka T, Kaneto H, Shiraiwa T, et al: Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation. Genes Dev. 20:1435–1440. 2006. View Article : Google Scholar : PubMed/NCBI
38	Lee JK, Edderkaoui M, Truong P, et al: NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases. Gastroenterology. 133:1637–1648. 2007. View Article : Google Scholar : PubMed/NCBI
39	Palagani V, Bozko P, El Khatib M, et al: Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression. Carcinogenesis. 35:859–866. 2014. View Article : Google Scholar : PubMed/NCBI
40	Butturini E, Carcereri de Prati A, Chiavegato G, et al: Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs. Free Radic Biol Med. 65:1322–1330. 2013. View Article : Google Scholar : PubMed/NCBI
41	Kim JK, Kim JY, Kim HJ, et al: Scoparone exerts anti-tumor activity against DU145 prostate cancer cells via inhibition of STAT3 activity. PLoS One. 8:e803912013. View Article : Google Scholar : PubMed/NCBI
42	Ørom UA, Kauppinen S and Lund AH: LNA-modified oligo-nucleotides mediate specific inhibition of microRNA function. Gene. 372:137–141. 2006.PubMed/NCBI
43	Lahdaoui F, Delpu Y, Vincent A, et al: miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Oncogene. 0:1–9. 2014.PubMed/NCBI
44	Zhao G, Wang B, Liu Y, et al: miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Mol Cancer Ther. 12:2569–2580. 2013. View Article : Google Scholar : PubMed/NCBI
45	Miao L, Xiong X, Lin Y, et al: miR-203 inhibits tumor cell migration and invasion via caveolin-1 in pancreatic cancer cells. Oncol Lett. 7:658–662. 2014.PubMed/NCBI
46	Huang F, Tang J, Zhuang X, et al: MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha. PLoS One. 9:e878972014. View Article : Google Scholar : PubMed/NCBI
47	Patel K, Kollory A, Takashima A, et al: MicroRNA let-7 down-regulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. Cancer Lett. 347:54–64. 2014. View Article : Google Scholar : PubMed/NCBI
48	Song S, Zhou J, He S, et al: Expression levels of microRNA-375 in pancreatic cancer. Biomed Rep. 1:393–398. 2013.PubMed/NCBI
49	Menghini R, Casagrande V, Marino A, et al: MiR-216a: a link between endothelial dysfunction and autophagy. Cell Death Dis. 5:e10292014. View Article : Google Scholar : PubMed/NCBI
50	Yang S, Wang X, Contino G, et al: Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25:717–729. 2011. View Article : Google Scholar : PubMed/NCBI